Posted on

cbd cures hiv

Cbd cures hiv

Moreover, people living with the disease were at high risk of illnesses we don’t see as frequently these days, including Kaposi’s sarcoma (a rare form of skin cancer), AIDS dementia, and the aforementioned HIV wasting syndrome.

Early Use of Marijuana in HIV

While the support for marijuana in the treatment of HIV wasting remains strong, research is still limited. Ultimately, many of the laws banning the use of marijuana in clinical settings have stifled robust scientific investigation. By contrast, studies supporting the use of Marinol have been relatively well established.

HIV-Associated Neuropathy

Many studies have confirmed a link between inhaling cannabis and pain relief. A 2013 study analyzing the effects among 23 people found that inhaling 25 mg of 9.4% THC three times per day for five days decreased pain and improved sleep quality.  

‡Complete blood count; AST, ALT, ALP, total bilirubin, urea, creatinine and blood glucose.

Scheduled visits will occur to monitor safety and tolerability, as per the visit schedule depicted in table 3 . Visits will include physical exam with vital signs, weight, occurrence of adverse events (AEs; and concomitant medications) and the presence of common symptoms associated with cannabinoids including dizziness, nausea, headaches, appetite or mood changes. At visits, blood for some or all of the following will be collected: CD4+ T cells count, CD8+ T cells, CD4/CD8 ratio, plasma viral load, complete blood count, AST, ALT, ALP, total bilirubin, urea, creatinine and blood glucose, T cell activation and inflammatory markers and testing for syphilis if the participant tested positive during the 4 weeks prior to beginning consuming the study capsules. A stool sample for analysis of the bacterial and fungal microbiome assessment will also be collected prior to beginning the study capsules. Participants will be enrolled in the study for up to 15 weeks but will consume capsules for a period of 12 weeks. Participants will undergo screening tests and eligibility assessment within 4 weeks prior to initiating study capsules. Participants will then undergo assessments after the first week of capsule consumption and every 2 weeks thereafter. A second stool sample for bacterial and fungal microbiome analysis will be collected during the final week of capsule consumption. The final visit will occur 2 weeks after study drug cessation.

In this pilot study, our primary objective is to assess the safety and tolerability of TN-TC11LM and TN-TC91LM taken by people living with HIV on suppressive ART. We hypothesise that these agents will be safe and well tolerated in people living with HIV, given that similar products are safe and well-= tolerated in other populations. Sativex is currently licenced as an adjunctive treatment for symptomatic relived of spasticity in adult patients with multiple sclerosis (MS) who have not responded adequately to other therapy. 78–80 It is an oromucosal spray containing CBD and THC in1:1 ratio. Marinol, which is a synthetic THC-containing capsule, is currently used for the treatment of anorexia associated with weight loss in persons with AIDS and nausea and vomiting associated with cancer chemotherapy in patients with insufficient response to conventional antiemetics. 81 It has been estimated that 5472 patients have been exposed to Sativex, and there have been no safety concerns identified and the product remains well tolerated. The primary safety concerns of both Sativex and Marinol are consistent with the known pharmacological activity of cannabinoids. The primary safety concerns associated with Sativex included abuse potential, cardiovascular effects and central nervous system AEs. 82 Although there is some evidence to suggest that individuals can develop ‘cannabis use disorder’, individuals do not develop the same extremes of behaviour as observed with other drugs of abuse. 83 In two clinical trials, nabiximols such as Sativex have been used in two clinical trials whereby treatment was abruptly ceased to study whether withdrawal symptoms would develop 84 85 In both studies, no withdrawal syndromes were observed. 86 Cannabinoids have cardiovascular effects that include tachycardia and fluctuations in blood pressure, including episodes of postural hypotension. Therefore, these agents should not be used in patients with serious cardiovascular disease, such as ischaemic heart disease, arrhythmias, poorly controlled hypertension or severe heart failure. THC has complex effects on the CNS and should not be used in patients with a personal or strong family history of psychosis. Examples of such conditions include schizophrenia and affective psychosis since symptoms of these disorders may be aggravated by cannabinoids. In Patients with MS receiving Sativex in clinical studies, psychiatric-related adverse effects included disorientation, depression including depressed mood, dissociation, euphoric mood, hallucination, hallucinations (auditory and visual), illusions, paranoia, suicidal ideation and delusional perception. 87 Interestingly, there is some evidence to demonstrate that CBD may actually improve psychotic symptoms in persons suffering from schizophrenia. 88

Clinical parameters

In addition, we decided to make our objective examining the ability of TN-TC11LM and TN-TC91LM capsules to reduce the HIV reservoir, through the reduction of systemic inflammation, an exploratory objective. It is unclear if 3 months of treatment will be long enough to produce any meaningful reduction in the size of the HIV reservoir. Furthermore, it is unclear what reduction in reservoir size is required to have a meaningful effect on clinical outcomes. As mentioned earlier, we will consider a 50% decrease in the number of HIV-infected cells at baseline versus week 12 to be a significant reduction in the reservoir based on a study by Hill et al. 71 To our knowledge, there is no other randomised clinical trial examining the effect of cannabinoids on inflammation and HIV reservoir size in people living with HIV.

The use of oral capsules containing precise amounts of cannabinoids, rather than smoked cannabis, ensures more predictable dosage administration and avoids the harmful pulmonary effects associated with smoking.

Table 2

Blood for HIV reservoir assessment will be collected at two time points prior to cannabis initiation (1 week prior to cannabinoid capsule initiation and immediately prior to cannabinoid capsule initiation) to account for normal fluctuations in baseline levels of HIV persistence markers. Subsequently, virological measures will be done at weeks 1, 2, 6, 8, 12 and 14. CD4+ T cells isolated form peripheral blood mononuclear cells (PBMCs) by magnetic negative selection. To capture all infected cells, the frequency of cells harbouring total and integrated HIV DNA will be measured using well-established assays on a total of 500 000 cells (sensitivity of 1 copy/reaction). 17 64 As most of the HIV genomes are defective, the recently developed ‘tat/rev induced limiting dilution assay’ (TILDA), which provides a more functional measurement of the HIV reservoir, 65 will be employed. To assess if residual levels of viral replication may occur, we will measure 2-LTR circles, which are proposed to be a surrogate marker for ongoing HIV replication during ART. 64 66 67 Specifically, this combination of assays will indicate if cannabis has an impact on the size of the total reservoir (DNA), the functional reservoir (TILDA) and ongoing viral replication (2-LTR circles). Measurements will be performed in batch.

The number of participants should provide insight into the degree of variability for continuous outcomes and should guide future sample size calculations for larger studies.